# US 2025/0026806 A1 · SIRPa VARIANT AND USE THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0026806 A1
- Document ID: US20250026806A1
- Status: Published application
- Kind: A1
- Application number: 18/710,479
- Filed: 2022-11-18
- Published: 2025-01-23
- Earliest claimed: 2021-11-19
- Assignees: Hangzhou Sumgen Biotech Co., Ltd.; Sumgen Mab (Beijing) Biotech Co., Ltd.
- Applicants: Hangzhou Sumgen Biotech Co., Ltd.; Sumgen Mab (Beijing) Biotech Co., Ltd.
- Inventors: Ming LV; Xiaoran DING; Shiwei MIAO; Bin TAN
- Web page: https://patentgrep.com/patent/US20250026806A1

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- C07K 14/70503: {Immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a SIRPα variant and a fusion protein thereof, capable of specifically blocking interaction between CD47 protein and SIRPα, not causing coagulation reaction, and capable of inhibiting growth and/or proliferation of tumors or tumor cells.

## Claims

### Claim 1

An SIRPα variant, comprising an amino acid substitution at the amino acid residue of N110, compared with a domain of the human SIRPα variant 1 or a fragment thereof.

### Claim 2 (depends on 1)

The SIRPα variant according to claim 1, wherein the domain of the human SIRPα variant 1 or fragment thereof comprises the amino acid residues at position 33-149 of the human SIRPα variant 1.

### Claim 3 (depends on 1)

The SIRPα variant according to claim 1, wherein the amino acid residues at position 33-149 of the human SIRPα variant 1 comprise the amino acid sequence as set forth in SEQ ID NO: 2.

### Claim 4 (depends on 1)

The SIRPα variant according to claim 1, comprising amino acid substitution N110A.

### Claim 5 (depends on 1)

The SIRPα variant according to claim 1, further comprising an amino acid substitution at one or more residues selected from the group consisting of: L44, I61, V63, E77, Q82, K83, E84, V93, D95, L96, K98, N100, R107, G109 and V132.

### Claim 6 (depends on 1)

The SIRPα variant according to claim 1, further comprising one or more amino acid substitutions selected from the group consisting of: L44V, I61L/V/F, V63I, E77I/N/Q/K/H/M/R/V/L, Q82S/R/G/N, K83R, E84Q/K/H/D/R/G, V93L/A, D95H/R/E, L96S/T, K98R, N100G/K/D/E, R107N/S, G109R/H and V132L/R/I/S.

### Claim 7 (depends on 1)

The SIRPα variant according to claim 1, comprising substitutions at amino acid residues selected from any of the following groups:
(1) I61, V63, E77, E84, V93, L96, K98, N100, N110 and V132;
(2) I61, E77, Q82, K83, E84 and N110;
(3) I61, V63, K83, E84, N110 and V132;
(4) I61, E77, E84, R107, N110 and V132;
(5) I61, V63, E77, K83, E84, N100 and N110;
(6) I61, E77, Q82, K83, E84, R107 and N110;
(7) I61, E77, Q82, E84, V93, L96, N100, R107, G109, N110 and V132;
(8) I61, E77, Q82, K83, E84, N110 and V132;
(9) I61 and N110;
(10) I61, D95, L96, G109, N110 and V132;
(11) I61, D95, L96, K98, G109, N110 and V132;
(12) I61, E77, E84, V93, R107, N110 and V132;
(13) E77, L96, N100, G109, N110 and V132;
(14) I61, V63, Q82, E84, D95, L96, N100, N110 and V132;
(15) I61, E77, Q82, K83, E84, V93, D95, L96, K98, N100, N110 and V132;
(16) I61, E77, Q82, K83, E84, V93 and N110;
(17) I61, V63, E77, K83, E84, D95, L96, K98, N100 and N110;
(18) I61, V63, E77, K83, D95, L96, K98, N100, G109 and N110;
(19) I61, E77, Q82, E84, V93, D95, L96, K98, N100 and N110;
(20) I61, V63, E77, Q82, E84 and N110; and
(21) L44, I61, E77, Q82, K83, E84, N110 and V132.

### Claim 8 (depends on 1)

The SIRPα variant according to claim 1, comprising amino acid mutations selected from any of the following groups:
(1) I61L, V631, E77I, E84K, V93L, L96S, K98R, N100G, N110A and V132L;
(2) I61V, E77N, Q82S, K83R, E84H and N110A;
(3) I61F, V63I, K83R, E84K, N110A and V132I;
(4) I61L, E77Q, E84D, R107N, N110A and V132I;
(5) I61L, V631, E77K, K83R, E84D, N100G and N110A;
(6) I61V, E77H, Q82R, K83R, E84H, R107S and N110A;
(7) I61L, E77I, Q82G, E84R, V93L, L96T, N100G, R107S, G109R, N110A and V132R;
(8) I61L, E77M, Q82G, K83R, E84D, N110A and V132L;
(9) I61L and N110A;
(10) I61F, D95H, L96S, G109H, N110A and V132S;
(11) I61F, D95H, L96S, K98R, G109H, N110A and V132S;
(12) I61L, E77Q, E84D, V93A, R107N, N110A and V132I;
(13) E77K, L96S, N100K, G109H, N110A and V132L;
(14) I61L, V631, Q82G, E84G, D95R, L96S, N100D, N110A and V132I;
(15) I61L, E77R, Q82N, K83R, E84G, V93L, D95E, L96T, K98R, N100D, N110A, and V132L;
(16) I61V, E77N, Q82S, K83R, E84H, V93A and N110A;
(17) I61V, V631, E77V, K83R, E84D, D95E, L96T, K98R, N100E and N110A;
(18) I61L, V631, E77V, K83R, D95E, L96S, K98R, N100D, G109R and N110A;
(19) I61V, E77L, Q82G, E84G, V93L, D95E, L96T, K98R, N100G and N110A;
(20) I61L, V631, E77N, Q82G, E84G and N110A; and
(21) L44V, I61F, E77I, Q82R, K83R, E84Q, N110A and V132I.

### Claim 9 (depends on 1)

The SIRPα variant according to claim 1, comprising the amino acid sequence as set forth in any one of SEQ ID NOs: 1, and 8-27.

### Claim 10 (depends on 1)

A fusion protein, comprising the SIRPα variant of claim 1, and an immunoglobulin Fc region.

### Claim 11 (depends on 10)

The fusion protein according to claim 10, wherein the immunoglobulin Fc region comprises an IgG Fc region or a variant thereof wherein the IgG is selected from the group consisting of IgG1, IgG2, IgG3 and IgG4.

### Claim 12

(canceled)

### Claim 13 (depends on 10)

The fusion protein according to claim 10, wherein the SIRPα variant is located at the N-terminus of the immunoglobulin Fc region.

### Claim 14 (depends on 10)

The fusion protein according to claim 10, wherein the immunoglobulin Fc region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-5.

### Claim 15 (depends on 10)

The fusion protein according to claim 10, comprising the amino acid sequence as set forth in any one of SEQ ID NOs: 6-7.

### Claim 16 (depends on 10)

The fusion protein according to claim 10, specifically binding to CD47 protein and having at least one of the following properties:
1) binding to CD47 protein with a KD value of 1×10−8M or lower;
2) specifically blocking the interaction between CD47 protein and SIRPα;
3) not inducing coagulation reaction; and
4) inhibiting the growth and/or proliferation of tumors or tumor cells.

### Claim 17 (depends on 16)

The fusion protein according to claim 16, wherein the CD47 protein is human CD47 protein.

### Claim 18 (depends on 1)

One or more isolated nucleic acid molecules, encoding the SIRPα variant of claim 1.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A composition, comprising the SIRPα variant of claim 1, and optionally a pharmaceutically acceptable adjuvant.

### Claim 23 (depends on 1)

A method of preventing or treating tumors or autoimmune diseases comprising administering to a subject in need thereof the SIRPα variant of claim 1, wherein the tumor is selected from the group consisting of CD47 positive hematological tumors or CD47 positive solid tumors.

### Claim 24

(canceled)

### Claim 25 (depends on 23)

The use according to claim 23, wherein the autoimmune disease is selected from the group consisting of Crohn's disease, allergic asthma and rheumatoid arthritis.

### Claim 26

(canceled)
